The atypical chemokine receptor-2 does not alter corneal graft survival but regulates early stage of corneal graft-induced lymphangiogenesis

Tian Yu 1 · J. V. Forrester 1,2,3 · Gerard J. Graham 4 · Lucia Kuffova 1,5

Received: 17 April 2018 / Revised: 27 June 2018 / Accepted: 12 July 2018 / Published online: 27 July 2018 © The Author(s) 2018

Abstract

Purpose To re-evaluate the role of the atypical chemokine receptor-2 (ACKR2) in corneal graft rejection and investigate the effect of ACKR2 on inflammation-associated lymphangiogenesis using murine orthotopic corneal transplantation.

Methods Corneal grafts were performed and evaluated in the settings of syngeneic, allogeneic and single antigen (HY-antigen) disparity pairings. Corneal vessels were quantified in whole mounts from WT, ACKR2−/− and F4/80−/−ACKR2−/− mice that received syngeneic or allogeneic grafts using anti-CD31 and anti-Lyve-1 antibodies.

Results Syngeneic corneal grafts in WT and ACKR2−/− mice were 100% accepted. Fully histo-incompatible allogeneic grafts were rapidly rejected (100%) with similar tempo in both WT and ACKR2−/− hosts. Around 50% of single-antigen (HY) disparity grafts rejected at a slow but similar tempo (60 days) in WT and ACKR2−/− mice. Prior to grafting, F4/80−/−ACKR2−/− mice had lower baseline levels of limbal blood and lymphatic vessels compared to ACKR2−/− mice. Syngeneic grafts, but not allogeneic grafts, in ACKR2−/− and F4/80−/−ACKR2−/− mice induced higher levels of lymphatic sprouting and infiltration of Lyve-1+ cells during the early (3d) post-graft (pg) stage but lymphatic density was similar to WT grafted mice by 7d pg.

Conclusions Our results indicate that the chemokine scavenger receptor, ACKR2, has no role to play in the survival of allogeneic grafts. A minor role in regulation of lymphangiogenesis in the early stage of wound healing in syngeneic grafts is suggested, but this effect is probably masked by the more pronounced lymphangiogenic inflammatory response in allogeneic grafts. No additional effect was observed with the deletion of the resident macrophage gene, F4/80.

Keywords ACKR2 · Corneal transplantation · Lymphangiogenesis · Angiogenesis · Graft rejection · Chemokines

Introduction

Corneal allograft rejection is predominantly mediated through the indirect pathway of allore cognition whereby newly recruited host antigen presenting cells (APC) process and present corneal alloantigens to naïve host T cells. The activation of an allospecific Th1 response then promotes the rejection of corneal allograft [reviewed in [1]]. Unlike allografts, syngeneic corneal grafts performed in naïve hosts are accepted indefinitely [2]. However, despite different outcomes, both corneal syngeneic and allogeneic grafts induce corneal hem- and lymph-angiogenesis which are considered to significantly affect the fate of the graft or the success of a second graft [3, 4].

The atypical chemokine receptor-2 (ACKR2, formerly known as D6) is a chemokine decoy receptor expressed mainly on afferent lymphatic endothelial cells (LEC) and innate-like B cells as well as some other leukocyte subsets such as...
dendritic cells (DC), macrophages and neutrophils [5] and has also recently been identified on a stromal fibroblastic population in the murine mammary gland [6]. Chemokine decoy receptors, such as ACKR2, have similar structures to conventional chemokine receptors, but they behave anomalously by binding chemokine ligands which fail to initiate G-protein-dependent signalling. Instead, engaged ligands are degraded after internalisation, and, in the case of ACKR2, the receptor is recycled back to the cell surface [5, 7]. ACKR2 recognises most pro-inflammatory CC chemokines with different affinity, but does not recognise homeostatic chemokines [5]. In this way, ACKR2 is regarded as a chemokine scavenger that regulates pro-inflammatory CC chemokine levels which in turn modulate immune responses.

Several studies have shown that ACKR2 is involved in the efficient resolution of inflammation. The absence of ACKR2 leads to more severe inflammatory disease associated with increased chemokine and leukocyte infiltrations [5, 8–10]. Furthermore, in a previous study, deletion of ACKR2 was reported to be associated with significantly increased rejection of corneal syngeneic grafts with nearly 60% of ACKR2−/− mice rejecting their syngrafts at 1 week post-surgery [11]. This is a surprising result since ACKR2−/− mice are fully histo-compatible with wild-type littermate mice and are in effect syngeneic grafts. However, the effect was ascribed to an elevated innate immune response in ACKR2−/− mice which, under sterile conditions of transplant surgery, implies involvement of damage-associated molecular patterns (DAMPs) [12]. Specifically, it was suggested that ACKR2 expressed by DC plays a role in modifying DC behaviour by promoting maturation and allosensitisation [11]. However, despite showing an impaired allospecific T cell response in ACKR2−/− mice, allograft survival was not different between WT and ACKR2−/− mice [11], suggesting that any such effect only affected syngeneic grafts.

An alternative role for ACKR2 function in the innate immune system has recently been suggested. ACKR2 regulates the embryonic development of lymphatic vessels, and that deletion of ACKR2 eventually leads to increased lymphatic vessel density in adult mice in a range of tissues including the skin, diaphragm, and lymph nodes [13]. This phenotype was associated with increased proximity of pro-lymphangiogenic macropathways to LEC in ACKR2−/− mice [13]. However, it is not clear whether ACKR2 is involved in inflammation-associated lymphangiogenesis in adult mice.

In view of the recognised importance of both chemokines [14] and lymphangiogenesis [4] in corneal graft rejection, we have re-investigated the role of ACKR2 in mouse corneal graft survival using ACKR2-deficient mice. In addition, in view of the proposed role of macrophages and DC in this process [11, 13], we have also evaluated corneal neovascularisation in ACKR2:F4/80 double gene deficient mice. F4/80 is expressed predominantly on resident tissue, suppressive macrophages and a subset of DC [15, 16]. We compared syngeneic, fully MHC incompatible allogeneic and single antigen disparity (HY) graft survival in WT and ACKR2−/− mice and evaluated blood and lymphatic corneal vessel growth in all groups of mice with syngeneic or allogeneic corneal grafts. We observed no difference in corneal graft survival between WT and ACKR2−/− in all settings tested while there was only a transient (first 3 days post-graft, [pg]) pro-lymphangiogenic effect on corneal vessels in ACKR2−/− mice. We are therefore unable to confirm a significant role for ACKR2 in the regulation of innate immune responses in the setting of murine corneal graft or in corneal syn- or allo-graft rejection.

Materials and methods

Mice

ACKR2−/− (background C57BL/6, H2b) and WT (H2b) littermates were used for all experiments. F4/80−/− mice (kindly provided by Professor Siamon Gordon, University of Oxford, UK) were crossed with ACKR2−/− mice to produce double knockout F4/80−/−ACKR2−/− mice (background C57BL/6, H2b). Female Balb/c (H2d) mice were used as donors for allogeneic corneal grafts. Syngeneic grafts were performed in WT to WT and ACKR2−/− to ACKR2−/− combinations. All mice were bred and kept at the Medical Research Facility, University of Aberdeen. Sex-matched 6–8-week-old mice were used in all experiments. All animals were treated in accordance with guidelines of the Association for Research in Vision and Ophthalmology (ARVO) Statement for the use of animals in ophthalmic and vision research and the regulations of the Animals (Scientific Procedures) Act 1986.

Orthotopic corneal transplantation

The mouse full-thickness orthotopic corneal transplantation was performed as described previously [17, 18]. Briefly, donor cornea marked with a 2.0 mm trephine was excised and sutured onto a 1.5-mm graft bed by one continuous suture using 11-0 Ethilon (Ethicon, New Jersey, USA). Grafted corneas were examined and monitored under an operating microscope after the procedure and corneal graft opacity scored as described previously [18]. Corneal graft opacity scores greater than or equal to 2 were considered as rejected grafts [18].

Corneal whole mount

Preparation of corneal whole mount was performed as previously described with modifications [17, 19]. The corneas including corneal limbus were excised together with the lens and fixed immediately in 4% paraformaldehyde at 4 °C for 30 min. The lens and iris were then removed from the corneas.
and the corneas were incubated in methanol for 20 min at room temperature. Permeabilization was performed by incubating the corneas in 0.3% Triton X-100 overnight at 4 °C. The corneas were then blocked with 10% normal mouse serum for 30 min at room temperature before incubated with rat anti-mouse CD31 (550274, BD Bioscience) and rabbit anti-mouse Lyve-1 (ab14917, Abcam, UK) antibodies diluted in PBS-BGEN (3% BSA, 0.25% gelatine, 5 mM EDTA and 0.025% IGEPAL CA-630 equivalent to Nonidet-P40) overnight at 4 °C. Directly conjugated secondary antibodies Alexa Fluor 555 goat anti-rat IgG (A21434, Invitrogen) and Alexa Fluor 488 goat anti-rabbit IgG (A11070, Invitrogen) diluted in PBS-BGEN were then incubated with the cornea for 2 h at room temperature. Corneas were washed 5 × 5 min between incubations with PBS. After staining, the corneas were mounted with Hydromount and imaged with Zeiss slide scanner (Zeiss Axio Scan.Z1, Zeiss, Jena, Germany).

Vessel quantification

Images acquired from corneal whole mounts were then analysed by the Volocity software (PerkinElmer, MA, USA) for areas of vessel coverage. The area of blood and lymphatic vessels was determined as between outer corneal limbal vessel arcade to the innermost end of newly formed vessels. For quantification of lymphangiogenesis, the numbers of sprouts and loops per cornea were quantified in a masked manner using the ImageJ software (National Institute of Health, USA) with the plug-in Lymphatic Vessel Analysis Protocol (LVAP).

Statistical analysis

GraphPad Prism (GraphPad Software, USA) was used for all statistical analysis. Log-rank test was used for comparison of corneal graft survival. For vessel quantifications, one-way ANOVA was used with Bonferroni post-test analysis. Statistical significance was considered when \( p < 0.05 \).

Results

Survival of murine corneal syngeneic and allogeneic grafts are unaffected by deletion of ACKR2

Syngeneic corneal grafts in naïve WT mice survive indefinitely [2, 20]. To confirm that deletion of ACKR2 alters graft survival in mice, we grafted sex-matched respective WT and ACKR2−/− donor corneas. No difference in graft survival or opacity score was observed in any combination of syngeneic graft for the duration of the experiment (60 days) (Fig. 1a). Furthermore, corneal graft opacity scores demonstrated that both WT and ACKR2−/− mice experienced similar levels of transient corneal opacification during the first week post-syngraft (Fig. 1b). This transient effect is known to be due to infiltration of innate immune cells caused by the surgery and by temporary distress of corneal endothelial cells [17, 18]. By the third week, all syngrafts were clear (Fig. 1b).

Rejection rate of single antigen (HY-antigen) disparity corneal grafts is not different between WT and ACKR2−/− mice

Fully mismatched, donor corneal allografts (Balb/c, H2d) to WT (C57BL/6, H2b) and ACKR2−/− recipients (H2b) were rapidly rejected with peak of rejection incidence occurring at day 13–18 pg and corneal opacity scores reaching 3 to 4 (Fig. 1a, c).
various inflammatory models [5], in part by facilitating lymph flow and migration of APC during inflammation [21, 22]. The lack of effect of ACKR2 in corneal syngeneic and allogeneic graft rejection was therefore surprising. However, it is possible that the strength of the alloreaction in fully mismatched corneal allograft has overwhelmed any possible effect of ACKR2 in chemokine regulation. Therefore, we evaluated graft survival in a single disparity, non-MHC pairing (HY-antigen) group by grafting male donor corneas to female recipients, comparing M-F WT grafts with M-F ACKR2−/− grafts on the C57BL/6 background. In this experiment, a milder rejection tempo was observed with graft rejection commencing 2 weeks post-surgery and approximately 50% of grafts rejected by 60 dp (Fig. 2a). However, there was no difference in corneal opacity or graft survival rate between WT and ACKR2−/− mice (Fig. 2a, b). As the corneal opacity scores, as well as the immunological status of recipient mice vary significantly between mice that accepted or rejected corneal grafts, the recipient mice were grouped into “rejectors” and “acceptors” according to corneal graft outcomes by day 60 pg and corneal opacity scores were re-analysed. When “rejectors” only were evaluated, the tempo of rejection was slightly increased in single disparity grafts but the absence of AKCR2 did not alter the rejection rate (Fig. 2c, d). Therefore, these findings indicate that ACKR2 does not play a significant role in the rejection or survival of corneal grafts.

Absence of ACKR2 leads to accelerated corneal lymphangiogenesis

Corneal graft rejection is associated with significant corneal vascularisation, including lymphangiogenesis [23]. ACKR2 is involved in regulating the establishment of lymphatic vessels during embryonic development mediated in part by prolymphangiogenic macrophages residing close to the developing lymphatics [13]. We sought to investigate whether ACKR2 is also required for regulating corneal inflammation-associated lymphangiogenesis during corneal graft. The cornea is normally avascular with vessels present only at the peripheral corneal limbus. Inflammation-associated corneal neovascularisation leads to the invasion of blood and lymphatic vessels towards the centre of cornea. Furthermore, macrophages play important roles in promoting corneal inflammation-associated lymphangiogenesis and studies have reported that the macrophage surface protein, F4/80, is required for ensuring the basal resting limbal lymphatic vessel numbers [24]. Lack of F4/80 has also been shown to be associated with a significantly reduced level of lymphangiogenesis in a model of corneal suture-induced neovascularisation [24]. Therefore, to investigate the role of ACKR2 and its association with macrophages in corneal lymphangiogenesis, quantification of corneal neovascularisation after corneal syngraft and allograft was performed in WT, disparity donor grafts (nWT = 22, nACKR2−/− = 19). Corneal grafts were subdivided into (c) “rejectors” (nWT = 11, nACKR2−/− = 9) and (d) “acceptors” (nWT = 11, nACKR2−/− = 10) and corneal opacity scores were compared between WT and ACKR2−/− mice. Statistical analysis was performed using Log-rank test for corneal graft survival and one-way ANOVA for corneal opacity scores.
ACKR2−/− and F4/80−/−ACKR2−/− mice. First, the baseline amount of limbal vessels in normal, non-transplanted mice was quantified by corneal whole mount imaging of CD31 and Lyve-1 staining and analysed by the Velocity software for area covered by blood and lymphatic vessels, respectively (Fig. 3a). Our data show that the levels of WT and ACRR2−/− corneal limbal vessels in the unchallenged eye were similar, whereas F4/80−/−ACKR2−/− mice had reduced levels of both blood (p < 0.01) and lymphatic vessels (p < 0.05) (Fig. 3a). Corneal graft induced marked vascularisation as expected but no difference in either blood or lymphatic vessel growth (measured by area at d3 and d7) was observed in any of the mice (Fig. 3b).

The process of lymphangiogenesis progresses through specific morphological stages including development of initial lymphatic sprouts, formation of lymphatic network/loops and finally maturation and remodelling of lymphatic vessels [25]. We therefore wished to determine whether ACKR2 or F4/80 had any effect on these processes during corneal graft rejection. We found that ACKR2−/− mice developed greater

Fig. 3 Quantification of normal corneal limbal vascularisation and neovascularisation post corneal graft. Corneal whole mounts were prepared from naïve or grafted (syngeneic and allogeneic) WT, ACKR2−/− (ACKR2), F4/80−/−ACKR2−/− (FA) mice and stained with anti-CD31 and anti-Lyve-1 antibodies for blood and lymphatic vessels, respectively. Corneal vascularisation was quantified by area covered by vessels (a) and corneal lymphangiogenesis was further assessed by lymphatic sprouts, loops and corneal infiltration of individual Lyve-1+ cells (c, e). (a) Quantification of normal corneal limbal blood and lymphatic vessels (nWT/nACKR2−/− = 6, nF4/80−/−ACKR2−/− = 5). (b) Quantification of blood and lymphatic vessels at day 3 (n = 5) and day 7 (n = 4) post-corneal syngeneic and allogeneic graft. (c) Evaluation of corneal lymphangiogenesis in syngeneic corneal grafts by lymphatic sprouts, corneal infiltration of individual Lyve-1+ cells and lymphatic loops formation (nday3 = 5, nday7 = 4). (d) Representative images of corneal syngeneic graft at day 3 pg stained with anti-Lyve-1 antibody. Corneal infiltration of individual Lyve-1+ cells is indicated by white arrows. Scale bar represents 250 μm. (e) Evaluation of lymphangiogenesis in corneal allografts at day 3 (n = 5) and day 7 pg (n = 4). Statistical significance was determined using one-way ANOVA, *p < 0.05, **p < 0.01, ***p < 0.001
numbers of sprouts compared to WT mice at 3 days post-syngeneic corneal graft (p < 0.05; Fig. 3c, d) and a similar trend between WT and F4/80−/−ACKR2−/− was observed (p < 0.001; Fig. 3c, d). However, no additional effect was seen in ACKR2−/− mice with co-deletion of F4/80 (Fig. 3c, d). Interestingly, the numbers of single Lyve-1+ cells (Fig. 3d, arrow) in the corneas followed the same trend in syngrafts at 3 d pg in that both ACKR2−/− (p < 0.05) and F4/80−/−ACKR2−/− mice (p < 0.01) showed increased infiltration of these cells compared to WT mice (Fig. 3c, d). These differences were not recapitulated in mice with syngeneic grafts at 7 d pg as suggested by similar number of loops between WT, ACKR2−/− and F4/80−/−ACKR2−/− mice (Fig. 3c). Furthermore, no difference in lymphangiogenic sprouts or loops was observed in allogeneic grafts at any time point between WT and ACKR2−/− or F4/80−/−ACKR2−/− mice (Fig. 3e). Thus, in the syngrafted ACKR2−/− and F4/80−/−ACKR2−/− mice, we have observed an accelerated initial lymphatic sprouting response together with increased abundance of Lyve-1+ individual cells. However, this did not lead to an increase in overall lymphatic vessel density.

Discussion

The role of ACKR2 in various inflammatory models is considered to be a general one of limiting excessive inflammation and promoting inflammatory resolution by “scavenging” inflammatory chemokines [5, 8–10]. Few studies have addressed the role of ACKR2 in allo-immunity [11, 26, 27]. Deletion of ACKR2 had a protective effect in graft-versushost disease attributed to increased numbers and enhanced immunosuppressive activity of Ly6C(high) monocytes [26] while a pro-inflammatory effect was observed in syngeneic but not allogeneic corneal grafts [11]. It was further proposed in this study that ACKR2 promoted DC maturation and T cell activation [11]. Thus, ACKR2 appears to promote innate immunity and in its absence the tempo of corneal allograft rejection might be expected to be reduced, while syngeneic grafts performed under sterile conditions should not be rejected. Counter-intuitively, syngeneic corneal grafts, which are universally accepted in uninfected mice [2, 18, 20] were reported to be rejected in ACKR2−/− mice while allogeneic corneal graft showed no difference in rejection rates between in WT and ACKR2−/− mice [11].

In view of the importance of chemokines to the corneal graft rejection process, not least because of possible translational and therapeutic implications, we considered it important to revisit the role of ACKR2 in corneal graft rejection. Using three different donor and recipient combinations (syngeneic, allogeneic and HY-antigen disparity), our data report no difference in corneal graft survival between WT and ACKR2−/− mice (Figs. 1 and 2). Importantly, in the previous study, C57BL/6 WT donor corneas were used for both WT and ACKR2−/− mice in syngeneic corneal grafts thus introducing an antigen disparity which may have affected their results [11]. However, the graft rejection rate did not follow the pattern of a single antigen disparity (see Fig. 2 herein) but was rather that of primary endothelial cell failure [18]. Differences in technique may explain the difference between the results of the present study and those of Hajrasoulia et al. [11]. No information is provided on the use of littermate controls in the previous study [11]. In addition, corneal grafts performed using interrupted sutures, as used in the previous study [11], cause significantly greater trauma and subsequent corneal opacity at week 1 pg compared to a continuous suture technique used here [18] and lead to greater inflammation and subsequent stress especially to the corneal endothelial cells [18]. Such technical issues will have a significant impact on innate immune activation.

Although we observed no difference in corneal graft rejection rates linked to ACKR2, the possibility that the process of lymphangiogenesis was altered could not be excluded, particularly since such changes had been observed in embryonic skin tissues in ACKR2−/− mice [13]. Overall, the level of peri-corneal limbal lymphatic vessels in resting ACKR2−/− mice was not different from naïve WT mice (Fig. 3a). This finding was not unexpected as the naïve corneal tissues are avascular with a narrow circumferential ring of limbal blood and lymphatic vessels. Whereas shown in the previous study, deletion of ACKR2 altered the density of lymphatic vessel network [13]. However, in agreement with a previous study in F4/80−/− mice [24], we observed that the levels of blood and lymphatic vessels at the corneal limbus in naïve F4/80−/−ACKR2−/− mice were significantly reduced compared to WT and ACKR2−/− mice (Fig. 3a). This suggests that F4/80+ macrophages are likely required for the development of normal corneal limbal vessels. Further support for this concept has been shown in the embryonic skin of WT and ACKR2−/− mice where two distinct populations of macrophages were identified namely CD11bhiF4/80loLyve-1− and CD11bhiF4/80hiLyve-1+ with the latter population expressing higher pro-angiogenic transcripts [13]. Moreover, previously reported experiments of corneal suture-induced lymphangiogenesis also revealed significant suppression of lymphangiogenesis in F4/80−/− mice compared to WT mice implicating an important role of F4/80+ macrophages in corneal lymphangiogenesis [24]. In contrast, we found that after corneal syngeneic graft, F4/80−/−ACKR2−/− mice had increased numbers of lymphatic sprouts and increased infiltration of single corneal Lyve-1+ cells compared to WT mice (Fig. 3c). Thus, our data suggest that the absence of ACKR2 promoted the recruitment of Lyve-1+ cells which may be capable of promoting the initial lymphatic sprouting and rescued the phenotype of impaired lymphangiogenesis in F4/80−/− mice as reported before [24]. The process of postnatal lymphangiogenesis is known to
involve the proliferation and differentiation of LEC after activation by pro-lymphangiogenic stimuli (e.g., vascular endothelial growth factors) and resulting in the sprouting of existing lymphatics [28]. However, increasing evidence supports the notion that bone marrow-derived lymph endothelial progenitor cells might differentiate into LEC and contribute to postnatal de novo lymphovasculogenesis in certain tissues during inflammatory response [23, 29–31]. Moreover, these cells may also play a paracrine role in promoting lymphangiogenesis by producing pro-lymphangiogenic cytokines [30]. The effect of ACKR2 and F4/80 was transient and restricted to the early stages of injury since no differences were observed at 7d pg in syngeneic grafts (Fig. 3c). It has been previously shown that syngeneic and allogeneic corneal grafts displayed similarly increased levels of chemokines as well as inflammatory cytokines at early time points (within 1 week pg) [32]. Thereafter, chemokine and cytokine levels remained high in the allogeneic group only, whereas in the syngeneic group, these levels declined significantly [32]. Furthermore, our findings coincide with a recent report that deletion of ACKR2 led to accelerated development of mammary gland branching associated with macrophage recruitment [6]. It was further shown that ACKR2 is differentially expressed in the mammary gland during different biological stages with maximum expression correlating with increased branching and macrophage recruitment in ACKR2−/− mice [6]. In addition, in vitro experiments demonstrated up-regulation of ACKR2 expression upon exposure to IFN-γ and IL-6 [22]. Therefore, ACKR2 in the current model is likely to function by regulating levels of inflammatory chemokines which in turn affects the recruitment of pro-lymphangiogenic Lyve-1+ cells during early time points (3d pg) after syngeneic grafts rather than allogeneic grafts. However at later time points where chemokine levels fall significantly in WT mice, ACKR2 may be less effective. Thus, together with our data, suggests that while ACKR2 may exert variable function during different stages of inflammation, we show here that ACKR2 plays a specific regulatory role of early inflammation-associated lymphangiogenesis in adult mouse.

Interestingly, this effect of ACKR2 on lymphangiogenesis was observed in early stages of inflammation of syngeneic grafts but not allogeneic grafts (Fig. 3e). Since the alloimmune response is more prominent and long lasting compared to the immune response to syngeneic grafts (which is, in effect, similar to an autologous corneal wounding response), we suggest that the strength of alloimmune response may mask a more subtle effect on simple wound healing responses. Alternatively, there may be an early suppression of lymph vessel sprouting mediated by the adaptive alloimmune response. This may merit further investigations.

In summary, we report that in contrast to a previous study [11], ACKR2 does not have a role to play in regulating corneal allograft responses. There is a minor effect mediated by ACKR2 during the early stages of lymphangiogenesis in corneal wound healing type responses, but this effect does not change final outcome of the transplanted corneal grafts.

**Funding** The work performed was supported by Saving Sight in Grampian (Charity No.SC002938). Saving Sight in Grampian provided financial support in the forming of Saving Sight in Grampian funding. The sponsor had no role in the design or conduct of this research.

**Compliance with ethical standards**

All animals were treated in accordance with guidelines of the Association for Research in Vision and Ophthalmology (ARVO) Statement for the use of animals in ophthalmic and vision research and the regulations of the Animals (Scientific Procedures) Act 1986.

**Conflict of interest** All authors certify that they have no affiliations with or involvement in any organisation or entity with any financial interest (such as honoraria; educational grants; participation in speakers’ bureaus; membership, employment, consultancies, stock ownership, or other equity interest; and expert testimony or patent-licensing arrangements), or non-financial interest (such as personal or professional relationships, affiliations, knowledge or beliefs) in the subject matter or materials discussed in this manuscript.

**Ethical approval** All applicable international, national and/or institutional guidelines for the care and use of animals were followed. All animals were treated in accordance with guidelines of the Association for Research in Vision and Ophthalmology (ARVO) Statement for the use of animals in ophthalmic and vision research and the regulations of the Animals (Scientific Procedures) Act 1986.

**Open Access** This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

**References**

1. Yu T, Rajendran V, Griffith M, Forrester JV, Kufflova L (2016) High-risk corneal allografts: a therapeutic challenge. World J Transplant 6(1):10–27. https://doi.org/10.5500/wjt.v6.i1.10
2. Sonoda Y, Streilein JW (1992) Orthotopic corneal transplantation in mice—evidence that the immunogenetic rules of rejection do not apply. Transplantation 54(4):694–704
3. Dohman TH, Omoto M, Hua J, Stevenson W, Lee SM, Chauhan SK, Dana R (2015) VEGF-trap aflibercept significantly improves long-term graft survival in high-risk corneal transplantation. Transplantation 99(4):678–686. https://doi.org/10.1097/TP.0000000000001512
4. Dietrich T, Bock F, Yuen D, Hos D, Bachmann BO, Zahn G, Wiegand S, Chen L, Cursiefen C (2010) Cutting edge: lymphatic vessels, not blood vessels, primarily mediate immune rejections after transplantation. J Immunol 184(2):535–539. https://doi.org/10.4049/jimmunol.0903180
5. Nibbs RJ, Graham GJ (2013) Immunoregulation by atypical chemokine receptors. Nat Rev Immunol 13(11):815–829
6. Wilson GJ, Hewit KD, Pallas KJ, Cairney CJ, Lee KM, Hansell CA, Stein T, Graham GJ (2016) Atypical chemokine receptor ACKR2 controls branching morphogenesis in the developing mammalian gland. Development. https://doi.org/10.1242/dev.139733
7. Weber M, Blair E, Simpson CV, O’Hara M, Blackburn PE, Rot A, Graham GJ, NBbs RJ (2004) The chemokine receptor D6 constitutively traffics to and from the cell surface to internalize and degrade chemokines. Mol Biol Cell 15(5):2492–2508. https://doi.org/10.1091/mbc.E03-09-0634
8. Jamieson T, Cook DN, NBbs RJ, Rot A, Nixon C, McLean P, Alcami A, Lira SA, Wiekowski M, Graham GJ (2005) The chemokine receptor D6 limits the inflammatory response in vivo. Nat Immunol 6(4):403–411. https://doi.org/10.1038/ni1182
9. Martinez de la Torre Y, Locati M, Buracchi C, Dupor J, Cook DN, Bonecchi R, Nebuloni M, Rukavina D, Vago L, Vecchi A, Lira SA, Mantovani A (2005) Increased inflammation in mice deficient for the chemokine decoy receptor D6. Eur J Immunol 35(5):1342–1346. https://doi.org/10.1002/eji.200526114
10. Di Liberto D, Locati M, Caccamo N, Vecchi A, Meraviglia S, Salerno A, Sireci G, Nebuloni M, Caceres N, Cardona PJ, Dieli F, Mantovani A (2008) Role of the chemokine decoy receptor D6 in balancing inflammation, immune activation, and antimicrobial resistance in Mycobacterium tuberculosis infection. J Exp Med 205(9):2075–2084. https://doi.org/10.1084/jem.20070608
11. Hajrasouliha AR, Sadrai Z, Lee HK, Chauhan SK, Dana R (2013) Expression of the chemokine decoy receptor D6 mediates dendritic cell function and promotes corneal allograft rejection. Mol Vis 19: 2517–2525
12. Todd J, Palmer SM (2017) Danger signals in regulating the immune response to solid organ transplantation. J Clin Invest 127(7): 2464–2472. https://doi.org/10.1172/JCI90594
13. Lee KM, Danuser R, Stein GJ, Graham D, NBbs RJ, Graham GJ (2014) The chemokine receptors ACKR2 and CCR2 reciprocally regulate lymphatic vessel density. EMBO J 33(21):2564–2580. https://doi.org/10.15252/embj.201488887
14. Wallace GR, John Curnow S, Wilko K, Salomon M, Murray PI (2004) The role of chemokines and their receptors in ocular disease. Prog Retin Eye Res 23(4):435–448. https://doi.org/10.1016/j.preteyeres.2004.04.004
15. Lin HH, Faunce DE, Stacey M, Terajewicz A, Nakamura T, Zhang-Hoover J, Kerley M, Muenscli ML, Gordon S, Stein-Streilein J (2005) The macrophage F4/80 receptor is required for the induction of antigen-specific effector regulatory T cells in peripheral tolerance. J Exp Med 201(10):1615–1625. https://doi.org/10.1084/jem.20042307
16. Gordon S, Hamann J, Lin HH, Stacey M (2011) F4/80 and the related adhesion-GPCRs. Eur J Immunol 41(9):2472–2476. https://doi.org/10.1002/eji.201141715
17. Kufflova L, Netukova M, Duncan L, Porter A, Stockinger B, Forrester JV (2008) Cross presentation of antigen on MHC class II via the draining lymph node after corneal transplantation in mice. J Immunol 180(3):1353–1361
18. Plskova J, Kufflova L, Holan V, Filipce M, Forrester JV (2002) Evaluation of corneal graft reaction in a mouse model. Br J Ophthalmol 86(1):108–113
19. Nakao S, Zandi S, Faez S, Kohno R, Hafezi-Moghadam A (2012) Discontinuous LYVE-1 expression in corneal limbal lymphatics: dual function as microvalves and immunological hot spots. FASEB journal: official publication of the Federation of American Societies for Experimental Biology 26(2):808–817. https://doi.org/10.1096/fj.11-183897
20. Yamada J, Streilein JW (1998) Fate of orthotopic corneal allografts in C57BL/6 mice. Transpl Immunol 6(3):161–168
21. Lee KM, McKimmie CS, Gilchrist DS, Pallas KJ, NBbs RJ, Garside P, McDonald V, Jenkins C, Ransohoff R, Liu L, Milling S, Cerovic V, Graham GJ (2011) D6 facilitates cellular migration and fluid flow to lymph nodes by suppressing lymphatic congestion. Blood 118(23):6220–6229. https://doi.org/10.1182/blood-2011-03-34044
22. McKimmie CS, Singh MD, Hewit K, Lopez-Franco O, Le Brocq M, Rose-John S, Lee KM, Baker AH, Wheat R, Blackbourn DJ, NBbs RJ, Graham GJ (2013) An analysis of the function and expression of D6 on lymphatic endothelial cells. Blood 121(18):3768–3777. https://doi.org/10.1182/blood-2012-04-425314
23. Maruyama K, Li M, Cursiefen C, Jackson DG, Keino H, Tomita M, Van Rooijen N, Takenaka H, D’Amore PA, Stein-Streilein J, Losordo DW, Streilein JW (2005) Inflammation-induced lymphangiogenesis in the cornea arises from CD11b-positive macrophages. J Clin Invest 115(9):2363–2372. https://doi.org/10.1172/JCI23874
24. Maruyama K, Nakazawa T, Cursiefen C, Maruyama Y, Van Rooijen N, D’Amore PA, Kinoshita S (2012) The maintenance of lymphatic vessels in the cornea is dependent on the presence of macrophages. Ophthalmol Vis Sci 53(6):3145–3153. https://doi.org/10.1167/iovs.11-8010
25. Tammela T, Altitalo K (2010) Lymphangiogenesis: molecular mechanisms and future promise. Cell 140(4):460–476. https://doi.org/10.1016/j.cell.2010.01.045
26. Savino B, Castor MG, Caronni N, Sarukhan A, Anselmo A, Buracchi C, Benvenuti F, Pinho V, Teixeira MM, Mantovani A, Locati M, Bonecchi R (2012) Control of murine Ly6C(high) monocyte traffic and immunosuppressive activities by atypical chemokine receptor D6. Blood 119(22):5250–5260. https://doi.org/10.1182/blood-2011-10-388082
27. Choi W, Byun YJ, Jung E, Noh H, Hajrasouliha AR, Sadrai Z, Chang E, Lee JH, Lee HK (2015) Chemokine decoy receptor D6 mimicking trap (D6MT) prevents allosensitization and immune rejection in murine corneal allograft model. J Leukoc Biol 97(2):413–424. https://doi.org/10.1189/jlb.3A0414-233RR
28. Kim H, Kataru RP, Koh GY (2014) Inflammation-associated lymphangiogenesis: a double-edged sword? J Clin Invest 124(3): 936–942. https://doi.org/10.1172/JCI71607
29. Kerjaschki D, Huttary N, Raab I, Reghe L, Bojasz-Nagy K, Bartel G, Krober SM, Greinix H, Rosenmaier A, Karthofer F, Wick N, Mazal PR (2006) Lymphatic endothelial progenitor cells contribute to de novo lymphangiogenesis in human renal transplants. Nat Med 12(2):230–234. https://doi.org/10.1038/nm1340
30. Lee JY, Park C, Cho YP, Lee E, Kim H, Kim P, Yun SH, Yoon YS (2010) Podoplanin-expressing cells derived from bone marrow play a crucial role in postnatal lymphatic neovascularization. Circulation 122(14): 1413–1425. https://doi.org/10.1161/CIRCULATIONAHA.110.941468
31. Hall KL, Volk-Draper LD, Flister MJ, Ran S (2012) New model of macrophage acquisition of the lymphatic endothelial phenotype. PLoS One 7(3):e31794. https://doi.org/10.1371/journal.pone.0031794
32. King WJ, Comer RM, Hudee T, Larkin DF, George AJ (2000) Cytokine and chemokine expression kinetics after corneal transplantation. Transplantation 70(8):1225–1233